公开(公告)号：WO2012070062A2

公开(公告)日：2012-05-31

申请号：PCT/IN2011/000779

申请日：2011-11-11

Applicant: HETERO RESEARCH FOUNDATION ,  PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  SRINIVASA RAO, Thungathurthy ,  VAMSI KRISHNA, Bandi

Inventor： PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  SRINIVASA RAO, Thungathurthy ,  VAMSI KRISHNA, Bandi

IPC: A61K31/506

CPC classification number: C07D401/14 ,  A61K31/506

Abstract: The present invention provides a novel crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical compositions comprising it.

Abstract translation: 本发明提供了盐酸尼洛替尼的新型结晶形式，其制备方法和包含其的药物组合物。

公开(公告)号：WO2012038971A3

公开(公告)日：2012-03-29

申请号：PCT/IN2011/000566

申请日：2011-08-23

Applicant: HETERO RESEARCH FOUNDATION ,  PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  RAMAKRISHNA REDDY, Matta ,  VAMSI KRISHNA, Bandi

Inventor： PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  RAMAKRISHNA REDDY, Matta ,  VAMSI KRISHNA, Bandi

IPC: C07D277/00

Abstract: The present invention provides a novel 1,4-dioxane solvate form of febuxostat and process for its preparation. The present invention also provides novel crystalline forms of febuxostat, processes for their preparation and pharmaceutical compositions comprising them.

公开(公告)号：WO2012001694A1

公开(公告)日：2012-01-05

申请号：PCT/IN2010/000441

申请日：2010-06-28

Applicant: HETERO RESEARCH FOUNDATION ,  PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  RAJI REDDY, Rapolu ,  RAMAKRISHNA REDDY, Matta ,  VAMSI KRISHNA, Bandi

Inventor： PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  RAJI REDDY, Rapolu ,  RAMAKRISHNA REDDY, Matta ,  VAMSI KRISHNA, Bandi

IPC: C07D257/04

CPC classification number: C07D405/14

Abstract: The present invention provides a process for the preparation of substantially pure trityl olmesartan medoxomil. The present invention also provides a process for purification of trityl olmesartan medoxomil. The present invention further provides a process for purification of olmesartan medoxomil.

Abstract translation: 本发明提供了制备基本上纯的三苯甲基奥美沙坦酯的方法。 本发明还提供了三苯甲基奥美沙坦酯的纯化方法。 本发明还提供了一种纯化奥美沙坦酯的方法。

公开(公告)号：WO2011132194A1

公开(公告)日：2011-10-27

申请号：PCT/IN2010/000247

申请日：2010-04-19

Applicant: HETERO RESEARCH FOUNDATION ,  PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  RAJI REDDY, Rapolu ,  RAMAKRISHNA REDDY, Matta ,  VASMI KRISHNA, Bandi

Inventor： PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  RAJI REDDY, Rapolu ,  RAMAKRISHNA REDDY, Matta ,  VASMI KRISHNA, Bandi

IPC: C07D407/00

CPC classification number: C07D333/56

Abstract: The present invention provides an improved process for the preparation of α-(3- methoxyphenylthio)-4-methoxyacetophenone. The present invention also provides a process for the preparing free flowing solid of 6-methoxy-2-(4-methoxyphenyl)- benzo[b]-thiophene. The present invention further provides a process for the preparation of substantially pure 6-methoxy-2-(4-methoxyphenyl)-benzo[b]-thiophene. The present invention further provides a process for purification of raloxifene hydrochloride.

Abstract translation: 本发明提供了制备α-（3-甲氧基苯硫基）-4-甲氧基苯乙酮的改进方法。 本发明还提供了制备6-甲氧基-2-（4-甲氧基苯基） - 苯并[b]噻吩的自由流动固体的方法。 本发明还提供了制备基本上纯的6-甲氧基-2-（4-甲氧基苯基） - 苯并[b]噻吩的方法。 本发明还提供了盐酸雷洛昔芬的纯化方法。

公开(公告)号：WO2011121592A1

公开(公告)日：2011-10-06

申请号：PCT/IN2010/000199

申请日：2010-03-29

Applicant: HETERO RESEARCH FOUNDATION ,  PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  RAJI REDDY, Rapolu ,  RAMAKRISHNA REDDY, Matta ,  VAMSI KRISHNA, Bandi

Inventor： PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  RAJI REDDY, Rapolu ,  RAMAKRISHNA REDDY, Matta ,  VAMSI KRISHNA, Bandi

IPC: C07D257/00 ,  C07D257/04

CPC classification number: C02F1/14 ,  C02F1/30 ,  C02F1/32 ,  C02F2001/007 ,  C02F2201/008 ,  C02F2209/003 ,  C02F2209/02 ,  C02F2303/04 ,  F24S23/77 ,  F24S25/00 ,  Y02A20/212 ,  Y02E10/47

Abstract: The present invention provides a process for the preparation of irbesartan substantially free of 3-((2'-(1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H- tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one (or) 3- ((2'-(2-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2H-tetrazol-5-yl)biphenyl-4- yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one impurity.

Abstract translation: 本发明提供了制备基本上不含3 - （（2' - （1 - （（2' - （1H-四唑-5-基）联苯-4-基）甲基）-1H-四唑的厄贝沙坦的方法 噻唑-5-基）联苯-4-基）甲基）-2-丁基-1,3-二氮杂螺[4.4]壬-1-烯-4-酮（或）3 - （（2' - （2 - （（ 2' - （1H-四唑-5-基）联苯-4-基）甲基）-2H-四唑-5-基）联苯-4-基）甲基）-2-丁基-1,3-二氮杂螺[4.4] 非1-烯-4-酮杂质。

公开(公告)号：WO2011117875A1

公开(公告)日：2011-09-29

申请号：PCT/IN2010/000189

申请日：2010-03-26

Applicant: HETERO RESEARCH FOUNDATION ,  PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  RAJI REDDY, Rapolu ,  VAMSI KRISHNA, Bandi ,  SRINIVASA REDDY, Puchakayala

Inventor： PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  RAJI REDDY, Rapolu ,  VAMSI KRISHNA, Bandi ,  SRINIVASA REDDY, Puchakayala

IPC: A01N43/38 ,  A61K31/40

CPC classification number: C07D209/24

Abstract: The present invention provides barium salt of fluvastatin, process for its preparation and pharmaceutical composition comprising it. The present invention also provides strontium salt of fluvastatin, process for its preparation and pharmaceutical composition comprising it. The present invention further provides novel process for the preparation of substantially amorphous fluvastatin sodium.

Abstract translation: 本发明提供了氟伐他汀的钡盐，其制备方法和包含它的药物组合物。 本发明还提供氟伐他汀的锶盐，其制备方法和包含其的药物组合物。 本发明还提供了制备基本无定形氟伐他汀钠的新方法。

公开(公告)号：WO2011114336A1

公开(公告)日：2011-09-22

申请号：PCT/IN2010/000149

申请日：2010-03-15

Applicant: HETERO RESEARCH FOUNDATION ,  PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  RAJI REDDY, Rapolu ,  VAMSI KRISHNA, Bandi ,  SUBASH CHANDER REDDY, Kesireddy ,  VENKATA RAMAKRISHNA REDDY, Isani

Inventor： PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  RAJI REDDY, Rapolu ,  VAMSI KRISHNA, Bandi ,  SUBASH CHANDER REDDY, Kesireddy ,  VENKATA RAMAKRISHNA REDDY, Isani

IPC: C07D473/00

CPC classification number: C07D473/18

Abstract: The present invention relates to process for isolation of ganciclovir intermediate. The present invention also provides a novel crystalline forms of ganciclovir, processes for their preparation and pharmaceutical composition comprising them. Thus, for example, to a mixture containing N-7 and N-9 isomer was added acetic acid and acetonitrile at 25 to 30 0 C to obtain a mass having a pH of 4.0 to 5.0, the reaction mass was cooled to -5 to -10 0 C and stirred for 3 hours at -5 to -10 0 C, filtered, washed with chilled acetonitrile and dried at 60 0 C for 4 hours to give N 2 -acetyl-9-(l,3-diacetoxy-2- propoxymethyl) guanine.

Abstract translation: 本发明涉及更昔洛韦中间体的分离方法。 本发明还提供更昔洛韦的新型结晶形式，其制备方法和包含它们的药物组合物。 因此，例如，在25〜300℃下，向含有N-7和N-9异构体的混合物中加入乙酸和乙腈，得到pH为4.0〜5.0的质量，将反应物质冷却至-5〜-100℃ 并在-5℃-100℃下搅拌3小时，过滤，用冷乙腈洗涤，在60℃下干燥4小时，得到N-乙酰基-9-（1,3-二乙酰氧基-2-丙氧基甲基）鸟嘌呤。

公开(公告)号：WO2011073993A1

公开(公告)日：2011-06-23

申请号：PCT/IN2009/000724

申请日：2009-12-16

Applicant: HETERO RESEARCH FOUNDATION ,  PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  RAJI REDDY, Rapolu ,  SUBASH CHANDER REDDY, Kesireddy ,  VAMSI KRISHAN, Bandi

Inventor： PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  RAJI REDDY, Rapolu ,  SUBASH CHANDER REDDY, Kesireddy ,  VAMSI KRISHAN, Bandi

IPC: C07D493/04

CPC classification number: C07D493/04 ,  A61K9/2027 ,  A61K9/2054 ,  A61K31/34

Abstract: The present invention provides novel solvated forms of darunavir and processes for there preparation. The present invention also provides novel process for preparation of darunavir amorphous form and pharmaceutical composition comprising it. Thus, for example, darunavir 2-methyl-2-butanol solvate was dissolved in methylene dichloride, distilled under vacuum at 45°C to obtain a residue, cyclohexane was added to the residue and stirred for 30 hours at 20 to 25°C, and the separated solid was filtered, washed with cyclohexane and dried under vacuum at 50°C for 12 hours to yield darunavir amorphous form.

Abstract translation: 本发明提供了地瑞那韦的新型溶剂化形式及其制备方法。 本发明还提供了地瑞那韦无定形形式的新方法和包含它的药物组合物。 因此，例如，将地瑞那韦2-甲基-2-丁醇溶剂化物溶解在二氯甲烷中，在45℃下真空蒸馏，得到残留物，将环己烷加入残渣中，在20〜25℃下搅拌30小时， 将分离的固体过滤，用环己烷洗涤，在50℃下真空干燥12小时，得到地诺拉维尔无定型。

公开(公告)号：WO2010004571A3

公开(公告)日：2010-12-29

申请号：PCT/IN2008000433

申请日：2008-07-07

Applicant: HETERO RESEARCH FOUNDATION ,  PARTHASARADHI REDDY BANDI ,  RATHNAKAR REDDY KURA ,  RAJI REDDY RAPOLU ,  MURALIDHARA REDDY DASARI ,  SAMBI REDDY JONNALA

Inventor： PARTHASARADHI REDDY BANDI ,  RATHNAKAR REDDY KURA ,  RAJI REDDY RAPOLU ,  MURALIDHARA REDDY DASARI ,  SAMBI REDDY JONNALA

IPC: C07D401/12

CPC classification number: C07D401/12

Abstract: There is provided a process for preparing amorphous rabeprazole sodium. Thus, for example, sodium hydroxide was dissolved in methanol. Rabeprazole was added to the solution and stirred at 25 - 35°C for 1 hour. Methanol was distilled off from the reaction mass, dichloromethane was added to the residual mass and the contents were stirred to obtain solution. The solution was added to cyclohexane. The contents were stirred at 25 - 35°C for 30 minutes, centrifuged the material and washed at 60 - 65°C to obtain amorphous rabeprazole sodium.

Abstract translation: 提供了制备无定形雷贝拉唑钠的方法。 因此，例如，将氢氧化钠溶解在甲醇中。 将雷贝拉唑加入到溶液中并在25-35℃下搅拌1小时。 从反应物料中蒸出甲醇，向剩余物中加入二氯甲烷，搅拌内容物得到溶液。 将溶液加入到环己烷中。 将内容物在25-35℃下搅拌30分钟，离心该物质并在60-65℃下洗涤得到无定形的雷贝拉唑钠。

公开(公告)号：WO2010079497A3

公开(公告)日：2010-07-15

申请号：PCT/IN2009/000034

申请日：2009-01-12

Applicant: HETERO RESEARCH FOUNDATION ,  PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  RAJI REDDY, Rapolu ,  MURALIDHARA REDDY, Dasari ,  SUBASH CHANDER REDDY, Kesireddy

Inventor： PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  RAJI REDDY, Rapolu ,  MURALIDHARA REDDY, Dasari ,  SUBASH CHANDER REDDY, Kesireddy

IPC: C07D213/56

Abstract: The present invention provides a novel crystalline form of atazanavir sulfate, process for its preparation and to pharmaceutical composition containing it. In accordance with the present invention atazanavir sulfate was dissolved in methanol, to the solution was added ethyl acetate, the solid obtained was collected by filtration and dried to give atazanavir sulfate crystalline form H1.